Join our “Ask the Ataxia Expert” session with Dr. Susan Perlman on May 12th at 11:30 AM CDT.  ADD TO CALENDAR

Blog

NAF Supports FARA’s Call to Action

Friedreich’s Ataxia Research Alliance (FARA) is encouraging Reata Pharmaceuticals to submit a New Drug Application (NDA) for Omaveloxolone, which recently completed a Phase III clinical trial as a treatment for Friedreich’s Ataxia (FA). FARA is also urging the Food and Drug Administration (FDA) to consider approving the NDA. FARA has Read More…

Print Friendly, PDF & Email

2019 NAF Funded Research Results

Below are lay summaries submitted for research completed in fiscal year 2019. Each study received a grant from NAF to support their research. To check out more information, click the “+” symbol next to the title of the study. Click the “-” symbol to collapse the lay summary for that Read More…

Print Friendly, PDF & Email

Ataxia Patient Advocacy Organizations Applaud the US Senate for Passing the Bipartisan “National Ataxia Awareness Day of 2020” Resolution

The National Ataxia Foundation (NAF) and the Friedreich’s Ataxia Research Alliance (FARA) applaud the United States Senate on behalf of Ataxia patients and their families for passing the National Ataxia Awareness Resolution of 2020 (S.Res. 717). Led by U.S Senator Elizabeth Warren (D-MA) and U.S. Senator Cindy Hyde-Smith (R-MS), this Read More…

Print Friendly, PDF & Email

Movement Disorder Advocacy: Making Policy a Priority

Guest Author: Movement Disorder Policy Coalition Movement disorders such as Ataxia, Parkinson’s, Huntington’s, and tardive dyskinesia can affect every aspect of a person’s life.  That includes the ability to work, travel, exercise, engage in leisure activities and interact with friends and family. But wise policymaking can help these people continue Read More…

Print Friendly, PDF & Email

National Ataxia Foundation Announces Launch of NAF Drug Development Collaborative

Pre-competitive pharma industry consortium looks to accelerate development of treatments for Ataxia The National Ataxia Foundation (NAF) announced today the launch of the NAF Drug Development Collaborative. This pre-competitive pharmaceutical industry consortium has a principal goal of accelerating the development of treatments for Ataxia. The group will address the many Read More…

Print Friendly, PDF & Email

Want to be a guest blogger?

Submit your name and blog topic. We’ll follow up with submission instructions.

Print Friendly, PDF & Email
Translate »